Twelve-Month Visual and Anatomical Outcomes of Boston Type I Keratoprosthesis in Four Patients with Multiple Graft Failures and Severe Ocular Pathology
Abstract
Purpose: To assess 12-month visual acuity, anatomic integrity, and complication rates after Boston Type I Keratoprosthesis (BKPro-I) implantation in eyes with multiple failed penetrating keratoplasties and complex anterior segment pathology. Methods: In this prospective case series, four eyes (mean age, 32 ± 9 years) received BKPro-I between January and June 2022. All surgeries employed polymethylmethacrylate front plates, customized titanium back plates, and a standardized perioperative regimen (IV cefazolin, topical vancomycin + levofloxacin, corticosteroid taper, nightly povidone-iodine, selective antifungal prophylaxis) with early 16 mm scleral lens fitting. Follow-up occurred at 3 days, 1 week, 2 weeks, monthly to 3 months, then quarterly to 12 months postoperatively. Primary outcomes were best-corrected visual acuity (BCVA), device retention, and sight-threatening complications. Results: At 12 months, all devices were retained. Functional success (BCVA ≥20/200) was achieved in 100% of eyes in 6 months; at 12 months, 75% reached ≥20/100 and 50% ≥20/60 (mean gain ≥5 ETDRS lines). Two eyes (50%) developed complications – retroprosthetic membranes, vitritis/suspected endophthalmitis, stromal melting, chronic hypotony, and silicone-oil leak – all managed without device loss; one eye’s vision declined to finger counting at month 7 but remained ambulatory. Conclusions: BKPro-I yields excellent short-term visual rehabilitation and perfect retention in highly complex eyes.…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.